Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE refuses to back Sanofi’s Jevtana

September 30, 2011
Sales and Marketing Jevtana, NICE

NICE has not recommended Sanofi’s prostate cancer drug Jevtana due to its high cost and concerns over its safety data. …

News

NICE blames pharma R&D model for spiralling cancer drug costs

September 29, 2011
Research and Development, Sales and Marketing Cancer, NICE, clincial trials

NICE has blamed the pharma industry’s ‘inefficient’ and increasingly costly R&D model for the rising price of cancer drugs. NICE …

News
Merck & Co

Merck’s COPD drug rejected by NICE

September 15, 2011
Sales and Marketing Daxas, MSD, Merck & Co, NICE, roflumilast

NICE has not recommended Merck Co’s Daxas and has advised the firm to conduct a clinical trial in order to …

News

NICE recommends Takeda’s cancer drug Mepact

September 7, 2011
Sales and Marketing Mepact, NICE, Takeda

NICE has reversed its stance on Mepact and recommended the bone cancer drug after re-examining discounts and a new patient …

News

NICE rejects three bowel cancer drugs

September 5, 2011
Sales and Marketing Erbitux, NICE, Vectibix, avastin, colorectal cancer

NICE says three treatments – Roche’s Avastin, Merck KgAa’s Erbitux and Amgen’s Vectibix – are all not cost effective in …

News

MSD sways NICE with Simponi patient access scheme

August 26, 2011
Sales and Marketing NICE, Simponi, ankylosing spondylitis

A patient access scheme which lowers Simponi’s cost has led to Merck Sharp and Dohme’s drug being given the thumbs …

News

NICE says no to BMS for second-line Orencia

August 25, 2011
Sales and Marketing BMS, NICE, Orencia, rheumatoid arthritis

In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have …

News

NICE blames Faslodex rejection on uncertainties in AZ data

August 23, 2011
Sales and Marketing AstraZeneca, Faslodex, NICE, breast cancer

NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness. In …

News
Novartis

New discount persuades NICE to back Novartis’ Tasigna

August 18, 2011
Sales and Marketing Glivec, NICE, Sprycel, Tasigna

NICE has recommended Novartis’ Tasigna for use in the NHS after the blood cancer drug’s manufacturer submitted a new patient …

News

NICE to review Lucentis decision

August 17, 2011
Sales and Marketing Lucentis, NICE, diabetic macular edema

NICE will allow an appeal against its decision not to recommend Novartis’s Lucentis for diabetic macular oedema. The appeal came …

News

NICE wants more information on Pradaxa

August 17, 2011
Sales and Marketing NICE, Pradaxa

NICE has asked for more information on Pradaxa, after deciding in preliminary guidance that the drug is not cost-effective in …

News

NICE wants more RoActemra data for juvenile idiopathic arthritis

August 9, 2011
Medical Communications NICE, RoActemra, Roche

NICE has requested more evidence from Roche for RoActemra in childhood arthritis. RoActemra (tocilizumab) is being assessed for the treatment …

News
Gilenya

Gilenya rejected by NICE

August 5, 2011
Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya

NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …

News
Janssen's Velcade (bortezomib)

NICE recommends thalidomide ahead of Velcade

July 27, 2011
Sales and Marketing NICE, Thalidomide, Velcade

NICE has recommended Celgene’s thalidomide ahead of J&J’s Velcade for multiple myeloma. Celgene’s drug is recommended in combination with an …

News

NICE consults on asthma drug reducing procedure

July 26, 2011
Sales and Marketing NICE, asthma

NICE has launched a consultation in the UK on a new medical procedure which, if it proves safe and effective, …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026